Human CCL24/Eotaxin-2/MPIF-2 enzyme-linked immunoassay kit
| Specification | 96 Test |
|---|---|
| Sensitivity | 0.75 pg/ml (50 μl)；9.71 pg/ml (10 μl)； |
| Standard Curve Range | 31.25~2000 pg/ml |
| Standard Curve Gradient | 7 Points |
| Number of Incubations | 2 |
| Detectable sample | Liquid phase sample of soluble substances. For example: serum, plasma, cell culture supernatant, tissue grinding liquid, etc. |
| Sample Volume | 50 μl/10 μl |
| Type | Fully Ready-to-Use |
| Operation Duration | 120min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0422 | 0.0372 | 0.0397 | |
| 31.25 | 0.0914 | 0.0879 | 0.0897 | 0.0500 |
| 62.50 | 0.1376 | 0.1466 | 0.1421 | 0.1024 |
| 125.00 | 0.2545 | 0.2710 | 0.2628 | 0.2231 |
| 250.00 | 0.5244 | 0.5137 | 0.5191 | 0.4794 |
| 500.00 | 1.0090 | 1.0250 | 1.0170 | 0.9773 |
| 1000.00 | 2.0390 | 2.0250 | 2.0320 | 1.9923 |
| 2000.00 | 3.3060 | 3.3210 | 3.3135 | 3.2738 |
Precision
| Intra-assay Precision | Inter-assay Precision | |||||
| Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
| 22 | 22 | 22 | 6 | 6 | 6 | |
| Average(pg/ml) | 341.7 | 1933.2 | 5656.0 | 396.7 | 1924.8 | 5724.1 |
| Standard Deviation | 25.4 | 50.6 | 153.1 | 30.8 | 36.8 | 93.0 |
| Coefficient of Variation(%) | 7.4 | 2.6 | 2.7 | 7.8 | 1.9 | 1.6 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty-two times on one plate to assess intra-assay precision. Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of human CCL24/Eotaxin-2/MPIF-2 into health human serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 105% to 126% with an overall mean recovery of 108%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (ng/ml) | Detectable (%) | Mean of Detectable (ng/ml) |
|---|---|---|---|---|
| Serum | 30 | 137.98-767.80 | 100.0 | 377.41 |
Serum/Plasma– Thirty samples from apparently healthy volunteers were evaluated for the presence of human CCL24/Eotaxin-2/MPIF-2 in this assay. No medical histories were available for the donors. n.d. = non-detectable. Samples measured below the sensitivity are considered to be non-detectable.
Product Data Sheet
Background: CCL24/Eotaxin-2/MPIF-2
Eotaxin, also named MPIF-2 and Ck beta 6, is a novel CC chemokine identified in the Human Genome Sciences, Inc. database based on the presence of the CC motif and homology with other known CC chemokines. Eotaxin-2 cDNA encodes a 119 amino acid residue precursor protein with a 26 aa residue signal peptide that is cleaved to generate a mature protein predicted to contain 93 amino acid residues with an N-glycosylation site. Although one recombinant preparation of MPIF‑2/Eotaxin‑2 from insect cells was reported to be glycosylated and of the predicted size (10.5 kDa), a second preparation of recombinant Eotaxin-2 prepared by a different group, also from insect cells, was shown to contain a 78 amino acid residue carboxy-terminally truncated variant of Eotaxin-2. Additional minor carboxy‑terminally truncated variants with 73, 75 and 76 residues were also isolated. Compared to other CC chemokines, Eotaxin-2 exhibits 40%, 42% and 39% amino acid identity to MCP-3, MIP-1 alpha, and Eotaxin, respectively. Eotaxin-2 mRNA is weakly expressed in activated monocytes and T lymphocytes.
Recombinant Eotaxin-2 has been shown to induce chemotaxis of eosinophils, basophils, and resting T lymphocytes but not monocytes and activated T lymphocytes. Eotaxin-2 has also been shown to suppress the colony formation by the high proliferative potential colony-forming cells which represent multipotential hematopoietic progenitors. On eosinophils, the effects of Eotaxin-2 was shown to be inhibited by an anti-CCR-3 antibody and to be cross-desensitized by Eotaxin or MCP-4, suggesting that all three CC chemokines act through CCR-3, at least on eosinophils.
